Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Josh J Carlson

Showing results (1-10 of 105) with videos related to

Pageof 11
Sort By:
Expert Review of Pharmacoeconomics & Outcomes Research|October 13, 2009
Erlotinib in non-small-cell lung cancer: a review of the clinical and economic evidenceJosh J Carlson
Journal of Managed Care & Specialty Pharmacy|December 24, 2021
Performance-based risk-sharing arrangements for devices and diagnostics in the United States: a systematic reviewYilin Chen, Josh J Carlson
Expert Review of Pharmacoeconomics & Outcomes Research|September 14, 2012
Clinical and economic review of erlotinib in non-small-cell lung cancerKai Yeung, Josh J Carlson
Clinical Lung Cancer|July 5, 2011
Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysisJoshua A Roth, Josh J Carlson
Breast Cancer Research and Treatment|August 27, 2013
The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysisJosh J Carlson, Joshua A Roth
Journal of Gastrointestinal Cancer|January 15, 2011
Cost-effectiveness of gemcitabine + cisplatin vs. gemcitabine monotherapy in advanced biliary tract cancerJoshua A Roth, Josh J Carlson
Journal of the National Cancer Institute|December 1, 2012
Proof or principle? On economic modeling to guide genomic testing in metastatic colorectal cancerJosh J Carlson, Scott D Ramsey
Journal of Managed Care & Specialty Pharmacy|September 26, 2017
Using Performance-Based Risk-Sharing Arrangements to Address Uncertainty in Indication-Based PricingKai Yeung, Meng Li, Josh J Carlson
Journal of Managed Care & Specialty Pharmacy|August 29, 2020
HTA'd in the USA: A Comparison of ICER in the United States with NICE in England and WalesPraveen Thokala, Josh J Carlson, Mike Drummond
Pharmacoeconomics|July 12, 2017
Performance-Based Risk-Sharing Arrangements: An Updated International ReviewJosh J Carlson, Shuxian Chen, Louis P Garrison
Pageof 11

Showing results (1-10 of 105) with videos related to

Sort By:
Pageof 11
Expert Review of Pharmacoeconomics & Outcomes Research|October 13, 2009
Erlotinib in non-small-cell lung cancer: a review of the clinical and economic evidenceJosh J Carlson
Journal of Managed Care & Specialty Pharmacy|December 24, 2021
Performance-based risk-sharing arrangements for devices and diagnostics in the United States: a systematic reviewYilin Chen, Josh J Carlson
Expert Review of Pharmacoeconomics & Outcomes Research|September 14, 2012
Clinical and economic review of erlotinib in non-small-cell lung cancerKai Yeung, Josh J Carlson
Clinical Lung Cancer|July 5, 2011
Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysisJoshua A Roth, Josh J Carlson
Breast Cancer Research and Treatment|August 27, 2013
The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysisJosh J Carlson, Joshua A Roth
Journal of Gastrointestinal Cancer|January 15, 2011
Cost-effectiveness of gemcitabine + cisplatin vs. gemcitabine monotherapy in advanced biliary tract cancerJoshua A Roth, Josh J Carlson
Journal of the National Cancer Institute|December 1, 2012
Proof or principle? On economic modeling to guide genomic testing in metastatic colorectal cancerJosh J Carlson, Scott D Ramsey
Journal of Managed Care & Specialty Pharmacy|September 26, 2017
Using Performance-Based Risk-Sharing Arrangements to Address Uncertainty in Indication-Based PricingKai Yeung, Meng Li, Josh J Carlson
Journal of Managed Care & Specialty Pharmacy|August 29, 2020
HTA'd in the USA: A Comparison of ICER in the United States with NICE in England and WalesPraveen Thokala, Josh J Carlson, Mike Drummond
Pharmacoeconomics|July 12, 2017
Performance-Based Risk-Sharing Arrangements: An Updated International ReviewJosh J Carlson, Shuxian Chen, Louis P Garrison
Pageof 11